Evidence for association of SNPs inABCB1andCBR3, but notRAC2, NCF4, SLC28A3orTOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines

Doxorubicin-induced cardiac dysfunction in unselected patients with a history of early-stage breast cancer

(2015) Megan E. V. Caram et al.   BREAST CANCER RESEARCH AND TREATMENT

Individual Prediction of Heart Failure Among Childhood Cancer Survivors

(2015) Eric J. Chow et al.   JOURNAL OF CLINICAL ONCOLOGY

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

(2015) Folefac Aminkeng et al.   NATURE GENETICS

Genetic variants inSLC22A17 and SLC22A7are associated with anthracycline-induced cardiotoxicity in children

(2015) Henk Visscher et al.   PHARMACOGENOMICS

Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology

(2014) D. L. Hertz et al.   CLINICAL CANCER RESEARCH

Prevention of Anthracycline-Induced Cardiotoxicity

(2014) Pimprapa Vejpongsa et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity

(2013) Daniel L Hertz et al.   JOURNAL OF HUMAN GENETICS

Validation of variants inSLC28A3andUGT1A6as genetic markers predictive of anthracycline-induced cardiotoxicity in children

(2013) H. Visscher et al.   PEDIATRIC BLOOD & CANCER

Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients

(2012) Pei Jye Voon et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Decline in the Use of Anthracyclines for Breast Cancer

(2012) Sharon H. Giordano et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients

(2011) Heloisa Sawaya et al.   AMERICAN JOURNAL OF CARDIOLOGY

Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children

(2011) Henk Visscher et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group

(2011) Javier G. Blanco et al.   JOURNAL OF CLINICAL ONCOLOGY

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

(2010) Lu Fan et al.   Pharmacogenetics and Genomics

Naturally Occurring Variants of Human CBR3 Alter Anthracycline In Vitro Metabolism

(2009) O. S. Bains et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21

(2009) D Rossi et al.   LEUKEMIA

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

(2009) J M Rae et al.   PHARMACOGENOMICS JOURNAL

Genetic polymorphisms in the carbonyl reductase 3 geneCBR3 and the NAD(P)H:quinone oxidoreductase 1 geneNQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

(2008) Javier G. Blanco et al.   CANCER

Late Cardiac Effects of Adjuvant Chemotherapy in Breast Cancer Survivors Treated on Southwest Oncology Group Protocol S8897

(2008) Patricia A. Ganz et al.   JOURNAL OF CLINICAL ONCOLOGY